Cutting Edge: In Vivo Blockade of Human IL-2 Receptor Induces Expansion of CD56bright Regulatory NK Cells in Patients with Active Uveitis
- 1 May 2005
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 174 (9) , 5187-5191
- https://doi.org/10.4049/jimmunol.174.9.5187
Abstract
In vivo blockade of the human IL-2R by mAb has been used for immunosuppression in transplantation, therapy for leukemia, and autoimmune diseases. In this study, we report that administration of a humanized IL-2R blocking Ab induced a 4- to 20-fold expansion of CD56bright regulatory NK cells in uveitis patients over time. The induced CD56bright regulatory NK cells from patients exhibited similar phenotype as those naturally occurring CD56bright cells. Patients with active uveitis had a significantly lower level of CD56bright NK cells compared with normal donors (p < 0.01). In addition, the induced CD56bright cells could secrete large amounts of IL-10 whereas CD56dim NK cells could not, suggesting that the induction of the CD56bright cells may have a beneficial effect on the remission of active uveitis. Our observation may have implications to IL-2R blockade therapy and for the potential role of CD56bright regulatory NK cells in autoimmune diseases.Keywords
This publication has 31 references indexed in Scilit:
- Remission of a Refractory, Anaplastic Large-Cell Lymphoma after Treatment with DaclizumabNew England Journal of Medicine, 2004
- Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell LeukemiaCancer Research, 2004
- Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationJournal of Autoimmunity, 2003
- What does it take to make a natural killer?Nature Reviews Immunology, 2003
- Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapyJournal of Clinical Investigation, 2000
- Emerging Therapies: Spectrum of Applications of Monoclonal Antibody TherapyHematology-American Society Hematology Education Program, 2000
- NKRP1A and p40 molecules are involved in regulation of activation and maturation of human NK cellsResearch in Immunology, 1997
- NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity.The Journal of Experimental Medicine, 1995
- Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.Journal of Clinical Investigation, 1993
- NKR-P1, a Signal Transduction Molecule on Natural Killer CellsScience, 1990